China TCR T Biotech NewCure Secures Fresh Funding for Solid Tumor Push

China’s cell therapy sector is drawing renewed investor interest as NewCure Biotech raised more than 200 million yuan, or about $28 million, in a Series B financing round to accelerate development of its TCR T pipeline targeting solid tumors. The round was co